Articles - Page 49 of 92 - Drugs in Context

The impact of antidepressants on depressive symptom severity, quality of life, morbidity, and mortality in heart failure: a systematic review

Rebecca Hedrick MD, Samuel Korouri BA, Emile Tadros BS, Tarneem Darwish MD, Veronica Cortez RN, OD, Desiree Triay RN, Mia Pasini RN, MSN, Linda Olanisa LCSW, Nathalie Herrera MD, Sophia Hanna BA, MA, Asher Kimchi MD, Michele Hamilton MD, Itai Danovitch MD, MBA, Waguih William IsHak MD, FAPA

Article Type

Original Research

Published

29 Jul 2020

This article reviews the literature on the impact of antidepressants on depressive symptom severity, quality of life, morbidity, and mortality in patients with heart failure.

Use of biologic agents and risk of tuberculosis in Brazil, a tuberculosis high-burden country

Fernanda Gomes Gonçalves Chaer MD, Juliana Miranda de Lucena Valim MD, Rogério Castro Reis MD, Giselle Burlamaqui Klautau PhD, Branca Dias Batista de Souza MSc

Article Type

Original Research

Published

28 Jul 2020

This study evaluated the frequency of tuberculosis infection in patients with rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis after the use of biologic agents in a single center of rheumatology.

Tinea corporis: an updated review

Alexander KC Leung MBBS, FRCPC, FRCP (UK and Irel), FRCPCH, FAAP, Joseph M Lam MD, FRCPC, Kin Fon Leong MBBS, MRCPCH, Kam Lun Hon MD, FAAP, FCCM

Article Type

Review

Published

20 Jul 2020

This article provides a narrative updated review on the evaluation, diagnosis, and treatment of tinea corporis.

Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus

Alexander KC Leung MBBS, FRCP (UK & Irel), FRCPCH, FAAP, Tara McMillan MD, FRCPC, Andrea Human MD, FRCPC, Joseph M Lam MD, FRCPC

Article Type

Case Report

Published

20 Jul 2020

Physicians who use hydroxychloroquine in children should be aware of this less-known side effect of hydroxychloroquine so that an accurate diagnosis can be made, and unnecessary investigations and inappropriate treatment can be avoided.

Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority metaanalytical approach

Philippe Lehert Dr Ir PhD, Cassandra Szoeke MD, GAICD, PhD, FRACP, AMA(M), MBBS

Article Type

Original Research

Published

08 Jul 2020

This research assesses the non-inferiority of pitolisant, a new compound for the relief of excessive daytime sleepiness and cataplexy in narcolepsy, compared with modafinil.